Trials / Completed
CompletedNCT00199290
A Phase2 Clinical Trial of Trafermin in Patients With Marginal Periodontitis in Japan
A Phase 2, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and the Safety of Trafermin in Patients With Marginal Periodontitis in Japan
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 267 (actual)
- Sponsor
- Kaken Pharmaceutical · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the efficacy and the safety of Trafermin(recombinant human basic fibroblast growth factor: rhbFGF) in Japanese patients with marginal periodontitis, in order to verify the superiority of Trafermin to placebo, and to determine the recommended therapeutic dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trafermin (genetical recombination) |
Timeline
- Start date
- 2005-08-01
- Primary completion
- 2007-07-01
- Completion
- 2007-12-01
- First posted
- 2005-09-20
- Last updated
- 2008-02-05
Locations
23 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00199290. Inclusion in this directory is not an endorsement.